Tetronothiodin, a novel CCKB receptor ligand, antagonizes cholecystokinin-induced Ca2+ mobilization in a pituitary cell line

• Published in: European journal of pharmacology Vol. 221; no. 1; p. 99
• Main Authors: Kuwahara, T, Kudoh, T, Nagase, H, Takamiya, M, Nakano, A, Ohtsuka, T, Yoshizaki, H, Arisawa, M
• Format: Journal Article
• Language: English
• Published: Netherlands 06.10.1992
• Subjects: Animals; Autoradiography; Binding Sites; Calcium - metabolism; Cell Line; Cholecystokinin - antagonists & inhibitors; Furans - pharmacology; Male; Pituitary Gland, Anterior - metabolism; Rats; Rats, Wistar; Receptors, Cholecystokinin - drug effects; Sincalide - metabolism; Thiophenes - pharmacology
• ISSN: 0014-2999
• DOI: 10.1016/0014-2999(92)90777-2

We found a novel nonpeptide CCKB receptor antagonist, tetronothiodin (Ro 09-1468), in the culture broth of Streptomyces sp. NR0489. The structure of the compound (C31O8H38S), which has a 19-membered ring with an alpha-acyltetronic acid and tetrahydrothiophene moiety, is completely different from that of any known CCK receptor antagonist. Tetronothiodin inhibited [125I]CCK-8 binding to rat brain CCKB receptors with an IC50 of 3.6 nM, whereas it showed only weak affinity for rat CCKA receptors (IC50 = 70 microM). As demonstrated autoradiographically, tetronothiodin concentration dependently inhibited [125I]CCK-8 binding to CCKB receptors in rat forebrain slices. The effects of tetronothiodin on cytosolic Ca2+ concentrations in GH3 cells, a rat anterior pituitary tumor cell line, were investigated with the fura-2 method. Tetronothiodin inhibited CCK-8-induced Ca2+ mobilization without affecting basal cytosolic Ca2+ concentrations. In conclusion, tetronothiodin is a new, potent and highly selective CCKB receptor antagonist. It is a useful tool for investigating the pharmacological and physiological roles of CCKB receptors.